Advertisement

Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Chapter

Abstracts

Worldwide, colorectal cancer is the third most commonly occurring cancer. Local recurrence and distance metastasis, especially in patients with low rectal cancers, present the main problems for surgeons. Even after undergoing total mesorectal excision (TME), the local recurrence rate for stage III patients is 20–30%. The available treatments of rectal cancers are far from satisfactory; the 5- and 10-year surgical rates are 35% and 22%, respectively. To improve the local control and long-term survival rates, it is necessary for patients with resectable stage II–III cancers to receive neoadjuvant therapy before undergoing surgery. Per the evidence, preoperative chemoradiotherapy (CRT) can significantly reduce the local recurrence of locally advanced rectal cancers and increase the rates of anus preservation. Hence, most guidelines, such as those of the National Comprehensive Cancer Network (NCCN), the European Society for Medical Oncology (ESMO), and the American Cancer Society (ACS), have strongly recommended the implementation of presurgery CRT as standard neoadjuvant therapy for locally advanced rectal cancers.

Keywords

Neoadjuvant therapy Rectal cancer Locally advanced Surgery Chemoradiotherapy 

References

  1. 1.
    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.  https://doi.org/10.1002/ijc.29210.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Dbeis R, Smart NJ, Daniels IR. Focusing the management of rectal cancer. Ann Transl Med. 2016;4(24):521.  https://doi.org/10.21037/atm.2016.11.80.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Trakarnsanga A, Ithimakin S, Weiser MR. Treatment of locally advanced rectal cancer: controversies and questions. World J Gastroenterol. 2012;18(39):5521–32.  https://doi.org/10.3748/wjg.v18.i39.5521.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Li Y, Wang J, Ma X, Tan L, Yan Y, Xue C, Hui B, Liu R, Ma H, Ren J. A review of neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Int J Biol Sci. 2016;12(8):1022–31.  https://doi.org/10.7150/ijbs.15438.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991;324:709–15.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114–23.CrossRefPubMedGoogle Scholar
  7. 7.
    NIH consensus conference: adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264:1444–50.Google Scholar
  8. 8.
    Madoff RD. Chemoradiotherapy for rectal cancer—when, why, and how? N Engl J Med. 2004;351(17):1790–2.CrossRefPubMedGoogle Scholar
  9. 9.
    Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R, German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.CrossRefGoogle Scholar
  10. 10.
    Belluco C, Forlin M, Olivieri M, Cannizzaro R, Canzonieri V, Buonadonna A, Bidoli E, Matrone F, Bertola G, De Paoli A. Long-term outcome of rectal cancer with clinically (EUS/MRI) metastatic mesorectal lymph nodes treated by neoadjuvant chemoradiation: role of organ preservation strategies in relation to pathologic response. Ann Surg Oncol. 2016;23:4302–9.  https://doi.org/10.1245/s10434-016-5451-5.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Arbea L, Ramos LI, Martínez-Monge R, Moreno M, Aristu J. Intensity-modulated radiation therapy (IMRT) vs. 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): dosimetric comparison and clinical implications. Radiat Oncol. 2010;5:1–9.CrossRefGoogle Scholar
  12. 12.
    Petrelli F, Sgroi G, Sarti E, Barni S. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer. Ann Surg. 2013;263(3):458–64.  https://doi.org/10.1097/SLA.0000000000000368.CrossRefGoogle Scholar
  13. 13.
    Heald RJ. The ‘Holy Plane’ of rectal surgery. J R Soc Med. 1988;81(9):503–8.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Frasson M, Garcia-Granero E, Roda D, Flor-lorente B. Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer. Cancer. 2011;117:3118–25.  https://doi.org/10.1002/cncr.25866.CrossRefGoogle Scholar
  15. 15.
    Weiser MR, Zhang Z, Schrag D. Locally advanced rectal cancer: time for precision therapeutics. Am Soc Clin Oncol Educ Book. 2015;35:e192–6.CrossRefGoogle Scholar
  16. 16.
    Hong TS, Kachnic LA. Preoperative chemoradiotherapy in the management of localized rectal cancer: the new standard. Gastrointest Cancer Res. 2007;1:49–56.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Kouyama Y, Kudo S-E, Miyachi H, Ichimasa K, Hisayuki T, Oikawa H, Matsudaira S, Kimura YJ, Misawa M, Mori Y, Kodama K, Kudo T, Hayashi T, Wakamura K, Katagiri A, Hidaka E, Ishida F, Hamatani S. Practical problems of measuring depth of submucosal invasion in T1 colorectal carcinomas. Int J Color Dis. 2016;31:137–46.CrossRefGoogle Scholar
  18. 18.
    Ong MLH, Schofield JB. Assessment of lymph node involvement in colorectal cancer. World J Gastrointest Surg. 2016;8:179–92.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Samdani T, Garcia-Aguilar J. Imaging in rectal cancer: magnetic resonance imaging versus endorectal ultrasonography. Surg Oncol Clin N Am. 2014;23:59–77.CrossRefPubMedGoogle Scholar
  20. 20.
    Ferrari L, Fichera A. Neoadjuvant chemoradiation therapy and pathological complete response in rectal cancer. Gastroenterol Rep. 2015;3(4):277–88.  https://doi.org/10.1093/gastro/gov039.CrossRefGoogle Scholar
  21. 21.
    Lombardi R, Cuicchi D, Pinto C, Di Fabio F, Iacopino B, Neri S, Tardio ML, Ceccarelli C, Lecce F, Ugolini G, Pini S, Di Tullio P, Taffurelli M, Minni F, Martoni A, Cola B. Clinically-staged T3N0 rectal cancer: is preoperative chemoradiotherapy the optimal treatment? Ann Surg Oncol. 2010;17:838–45.  https://doi.org/10.1245/s10434-009-0796-7.CrossRefPubMedGoogle Scholar
  22. 22.
    Cedars Sinai. Rectal cancer. NCCN Clinical Practice Guidelines in Oncology, versuib 2. 2017. Retrieved from http://www.cedars-sinai.edu/Patients/Programs-and-Services/Colorectal-Cancer-Center/Services-and-Treatments/Rectal-Cancer.aspx
  23. 23.
    Jo P, Nietert M, Gusky L, Kitz J, Conradi LC, Müller-Dornieden A, Schüler P, Wolff HA, Rüschoff J, Ströbel P, Grade M, Liersch T, Beißbarth T, Ghadimi MB, Sax U, Gaedcke J. Neoadjuvant therapy in rectal cancer - biobanking of preoperative tumor biopsies. Sci Rep. 2016;6:35589.  https://doi.org/10.1038/srep35589.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Snijders HS, Leersum NJ, Van Henneman D, Vries AC, De Tollenaar RAEM, Stiggelbout AM, Wouters MW, Dekker JWT. Optimal treatment strategy in rectal cancer surgery: should we be cowboys or chickens? Ann Surg Oncol. 2015;22(11):3582–9.  https://doi.org/10.1245/s10434-015-4385-7.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Brændengen M, Tveit KM, Berglund Å, Birkemeyer E, Gunilla Frykholm LP, Wiig JN, Byström P, Bujko K, Glimelius B. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol. 2008;26(22):3687–94.  https://doi.org/10.1200/JCO.2007.15.3858.A.CrossRefPubMedGoogle Scholar
  26. 26.
    Gunderson LL, Sosin H. Areas of failure found at reoperation (secondor symptomatic look) following curative surgery for adenocarcinoma ofthe rectum: clinicopathologic correlation and implications foradjuvant therapy. Cancer. 1974;34:1278–92.CrossRefPubMedGoogle Scholar
  27. 27.
    Higgins GA, Humphrey EW, Dwight RW, et al. Preoperative radiation and surgery for cancer of the rectum. Veterans administration surgical oncology group trial II. Cancer. 1986;58(2):352–9.CrossRefGoogle Scholar
  28. 28.
    Izar F, Fourtanier G, Pradere B, et al. Pre-operative radiotherapy as adjuvant treatment in rectal cancer. Cancer. 1992;16(1):106–11. Discussion 111–2.Google Scholar
  29. 29.
    Hyams DM, Mamounas EP, Petrelli N, et al. A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: a progress report of National Surgical Breast and Bowel Project Protocol R-03. Dis Colon Rectum. 1997;40(2):131.CrossRefPubMedGoogle Scholar
  30. 30.
    Aklilu M, Eng C. The current landscape of locally advanced rectal cancer. Nat Rev Clin Oncol. 2011;8(11):649–59.CrossRefPubMedGoogle Scholar
  31. 31.
    Lai LL, Fuller CD, Kachnic LA, et al. Can pelvic radiotherapy be omitted in select patients with rectal cancer? Semin Oncol. 2006;33(11):70–4.CrossRefGoogle Scholar
  32. 32.
    Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926–33.  https://doi.org/10.1200/JCO.2011.40.1836.CrossRefGoogle Scholar
  33. 33.
    Bosset JF, Pavy JJ, Hamers HP, et al. Determination of the optimal dose of 5-fluorouracil when combined with low dose D,L-leucovorin and irradiation in rectal cancer: results of three consecutive phase II studies. Eur J Cancer. 1993;29A:1406–10.CrossRefPubMedGoogle Scholar
  34. 34.
    Bosset JF, Calais G, Mineur L, et al. Enhanced tumoricidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results—EORTC 22921. J Clin Oncol. 2005;23:5620–7.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Bosset JF, Calais G, Daban A, et al. Pre-operative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance—report of the 22921 randomised trial conducted by the EORTC Radiotherapy Group. Eur J Cancer. 2004;40:219–24.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery: the clue to pelvic recurrence? Br J Surg. 1982;82:613–6.CrossRefGoogle Scholar
  37. 37.
    Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997;336:980–7.CrossRefGoogle Scholar
  38. 38.
    Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, van de Velde CJ. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638–46.CrossRefGoogle Scholar
  39. 39.
    Shi C, Zhou H, Li X, Cai Y. A retrospective analysis on two-week short-course pre-operative radiotherapy in elderly patients with resectable locally advanced rectal cancer. Sci Rep. 2016;6:37866.  https://doi.org/10.1038/srep37866.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Wang L, Li YH, Cai Y, Zhan TC, Gu J. Intermediate neoadjuvant radiotherapy combined with total mesorectal excision for locally advancd rectal cancer: outcomes after a median follow-up of 5 years. Clin Colorectal Cancer. 2016;15(2):152–7.CrossRefPubMedGoogle Scholar
  41. 41.
    Liu G, Yan J, He Q, An X, Pan Z, Ding P. Effect of neoadjuvant chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a meta-analysis. Gastroenterol Res Pract. 2016;2016:1–10.  https://doi.org/10.1155/2016/1798285.CrossRefGoogle Scholar
  42. 42.
    Allegra CJ, Yothers G, O’Connell MJ, Beart RW, Wozniak TF, Pitot HC, Shields AF, Landry JC, Ryan DP, Arora A, Evans LS, Bahary N, Soori G, Eakle JF, Robertson JM, Moore DF, Mullane MR, Marchello BT, Ward PJ, Sharif S, Roh MS, Wolmark N. Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase III randomized clinical trial. J Natl Cancer Inst. 2015;107:djv248.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti P, Bonetti A, Negru ME, Tronconi MC, Luppi G, Silvano G, Corsi DC, Bochicchio AM, Chiaulon G, Gallo M, Boni L. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29:2773–80.CrossRefPubMedGoogle Scholar
  44. 44.
    Gérard J-P, Azria D, Gourgou-Bourgade S, Martel-Lafay I, Hennequin C, Etienne P-L, Vendrely V, François E, de La Roche G, Bouché O, Mirabel X, Denis B, Mineur L, Berdah J-F, Mahé M-A, Bécouarn Y, Dupuis O, Lledo G, Seitz J-F, Bedenne L, Juzyna B, Conroy T. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol. 2012;30:4558–65.CrossRefPubMedGoogle Scholar
  45. 45.
    Machiels JP, Sempoux C, Scalliet P, et al. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann Oncol. 2007;18:738–44.CrossRefPubMedGoogle Scholar
  46. 46.
    Bertolini F, Chiara S, Bengala C, et al. Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab,and pelvic radiotherapy: a phase II study in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2009;73:466–72.CrossRefPubMedGoogle Scholar
  47. 47.
    Rodel C, Arnold D, Hipp M, et al. Phase I-II trial of cetuximab,capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys. 2008;70:1081–6.CrossRefPubMedGoogle Scholar
  48. 48.
    Horisberger K, Treschl A, Mai S, et al. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a phase II MARGIT trial. Int J Radiat Oncol Biol Phys. 2009;74:1487–93.CrossRefPubMedGoogle Scholar
  49. 49.
    Kim SY, Hong YS, Kim DY, et al. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter phase II study. Int J Radiat Oncol Biol Phys. 2011;81(3):677–83.CrossRefPubMedGoogle Scholar
  50. 50.
    Dewdney A, Cunningham D, Tabernero J, et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol. 2012;30(14):1620–7.CrossRefPubMedGoogle Scholar
  51. 51.
    Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, Lahdenranta J, Chung DC, Fischman AJ, Lauwers GY, Shellito P, Czito BG, Wong TZ, Paulson E, Poleski M, Vujaskovic Z, Bentley R, Chen HX, Clark JW, Jain RK. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol. 2009;27:3020–6.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Crane CH, Eng C, Feig BW, Das P, Skibber JM, Chang GJ, Wolff RA, Krishnan S, Hamilton S, Janjan NA, Maru DM, Ellis LM, Rodriguez-Bigas MA. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2010;76:824–30.CrossRefPubMedGoogle Scholar
  53. 53.
    Velenik V, Ocvirk J, Music M, Bracko M, Anderluh F, Oblak I, Edhemovic I, Brecelj E, Kropivnik M, Omejc M. Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study. Radiat Oncol. 2011;6:105.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Salazar R, Capdevila J, Laquente B. A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features. BMC Cancer. 2015;15:60.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Gasparini G, Torino F, Ueno T, Cascinu S, Troiani T, Ballestrero A, Berardi R, Shishido J, Yoshizawa A, Mori Y, Nagayama S, Morosini P, Toi M. A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. Angiogenesis. 2012;15:141–50.CrossRefPubMedGoogle Scholar
  56. 56.
    Landry JC, Feng Y, Cohen SJ, Staley CA. Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204. Cancer. 2013;119(8):1521–7.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Ludmir EB, Palta M, Willett CG, Czito BG. Total neoadjuvant therapy for rectal cancer: an emerging option. Cancer. 2017;123:1497–506.CrossRefGoogle Scholar
  58. 58.
    Sclafani F, Cunningham D. Neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer. Future Oncol. 2014;10(14):2243–57.CrossRefPubMedGoogle Scholar
  59. 59.
    Fernandez-Martos C, Pericay C, Aparicio J, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant hemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol. 2010;28(5):859–65.CrossRefGoogle Scholar
  60. 60.
    Ishii Y, Hasegawa H, Endo T, et al. Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil,and leucovorin in patients with locally advanced rectal cancer. Eur J Surg Oncol. 2010;36:1061–5.CrossRefPubMedGoogle Scholar
  61. 61.
    Uehara K, Hiramatsu K, Maeda A, et al. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapyfor poor-risk rectal cancer: N-SOG 03 phase II trial. Jpn J Clin Oncol. 2013;43:964–71.CrossRefPubMedGoogle Scholar
  62. 62.
    Hasegawa J, Nishimura J, Mizushima T, et al. Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer. Cancer Chemother Pharmacol. 2014; 73:1079–87.CrossRefPubMedGoogle Scholar
  63. 63.
    Schrag D, Weiser MR, Goodman KA, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol. 2014;32:513–8.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Trakarnsanga A, Gonen M, Shia J, et al. What is the significance of the circumferential margin in locally advanced rectal cancer after neoadjuvant chemoradiotherapy? Ann Surg Oncol. 2013;20:1179–84.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Glimelius B, Tiret E, Cervantes A, et al. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(6):81–8.Google Scholar
  66. 66.
    Wang Q-X, Li S-H, Zhang X, Xie L, Cai P-Q, An X, et al. Identification of locally advanced rectal cancer with low risk of local recurrence. PLoS One. 2015;10(1):e0117141.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    MERCURY Study Group. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology. 2007;243(1): 132–9.Google Scholar
  68. 68.
    Mass M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11:835–44.CrossRefGoogle Scholar
  69. 69.
    Sun YS, Zhang XP, Tang L, Ji JF, Gu J, Cai Y, Zhang XY. Locally advanced rectal carcinoma treated with preoperative chemotherapy and radiation therapy: preliminary analysis of difussion-weighted MR imaging for early detection of tumor histopathologic downstaging. Radiology. 2009;254:170–8.CrossRefPubMedGoogle Scholar
  70. 70.
    Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29(35):4633.CrossRefGoogle Scholar
  71. 71.
    Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U Jr, Silva e Sousa AH Jr, Campos FG, Kiss DR, Gama- Rodrigues J. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long term results. Ann Surg. 2004;240:711–7.PubMedPubMedCentralGoogle Scholar
  72. 72.
    Hernandez-Carcia I, Viudez A, Suarez J, et al. Clinical complete response in locally advanced rectal cancer: can we offer a wait-and-see policy? Ann Oncol. 2013;24(3):853.CrossRefGoogle Scholar
  73. 73.
    Kwak YK, Kim K, Lee JH, et al. Timely tumor response analysis after preoperative chemoradiotherapy and curative surgery in locally advanced rectal cancer: a multi-institutional study for optimal surical timing in rectal cancer. Radiother Oncol. 2016;119(3):512–8.CrossRefPubMedGoogle Scholar
  74. 74.
    Lefevre JH, Mineur L, Kotti S, et al. Effect of interval (7 or 11 weeks) between neoaduavant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol. 2016;34:3773.CrossRefPubMedGoogle Scholar
  75. 75.
    Bujko K, Nowacki MP, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93:1215–23.  https://doi.org/10.1002/bjs.5506.CrossRefGoogle Scholar
  76. 76.
    Trotti A, Barthel JS, Kim CJ, Yeatman TJ, Coppola D, Trotti A, Williams B. Local excision of T2 and T3 rectal cancers after downstaging chemoradiation. Ann Surg. 2001;234(3):352–9.  https://doi.org/10.1097/00000658-200109000-00009.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Department of Colorectal SurgeryPeking University Cancer HospitalBeijingPeople’s Republic of China

Personalised recommendations